Stock Ratings / Health Care / OBX / news

ALMS (23) JBIO (36) IVA (61) ANRO (38) ⌘ Pro Terminal →

Why OBX Stock slipped -0.48% Today — RQD Quant Desk Flash

$14.52 -0.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Obsidian Therapeutics Inc. (OBX) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $896.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OBX)Realized 20D OHLCV Swing Band: ±12.5%

AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why OBX Stock slipped -0.48% Today — RQD Quant Desk Flash

Obsidian Therapeutics Inc. (OBX) slipped -0.48% to $14.52, trading at 8% of its 52-week range ($11.52 – $49.97). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

▸Technical Tape: Trading at 8% of its 52-week range ($11.52 – $49.97) with RSI-14 at 55.6 (BULLISH MOMENTUM).
▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $14.52 (no active unusual options sweep snapshot on file).
▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.

Live OBX Headlines & Catalysts

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OBX)

✓Walkthrough of OBX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OBX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -17.03%▲ RESISTANCE BREAKOUT

2026-10-30O $14.55H $15.52L $13.66C $14.52VOL 563.0K

RES: $13.35SUP: $11.16SMA50: $15.29SMA200: $17.28

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OBX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OBX Butterfly Map → + Track OBX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OBX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OBX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OBX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OBX)

Health Care Rank #665 of 1016 ⚔️ ALMS vs OBX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OBX vs. ALMS, JBIO, IVA, ANRO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Obsidian Therapeutics Inc. (OBX) ranks #665 by composite RQD confidence (39/100, grade D-) and #377 by equity capitalization ($896.9M). Within this direct 5-issuer industry benchmark cohort, OBX leads on earnings valuation at N/A trailing P/E, while OBX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IVA currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with OBX at 39/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OBX ACTIVE Obsidian Therapeutics Inc.	D-	39/100	—	—	-35.0%	-0.48%	$896.9M	Benchmark Subject
ALMS Alumis Inc.	E	23/100	—	—	-35.0%	-3.37%	$891.8M	/alms-vs-obx →
JBIO Jade Biosciences Inc.	D-	36/100	—	—	-35.0%	-2.40%	$905.6M	/jbio-vs-obx →
IVA Inventiva S.A. American Depository Shares	C-	61/100	—	—	—	+0.54%	$881.3M	/iva-vs-obx →
ANRO Alto Neuroscience Inc.	D-	38/100	—	—	-35.0%	+0.60%	$921.0M	/anro-vs-obx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002130606

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Obsidian Therapeutics Inc. (OBX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$100.6M, operating cash flow of -$90.4M, and free cash flow of -$90.5M (-19.4% YoY). On the balance sheet, OBX closed FY2025 with $88.6M in total assets against $0 in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$100.6M	-$90.4M	-$90.5M	$88.6M	—
FY2024 (FY)	2024-12-31	$0	-$83.1M	-$75.0M	-$75.8M	$183.7M	—

3. OBX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OBX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Obsidian Therapeutics Inc. (NASDAQ: OBX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $14.52 (-0.48% 1D, market cap $896.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OBX ranks #665 in composite RQD confidence.

How does OBX compare to ALMS and JBIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OBX carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ALMS (Alumis Inc.) holds a E grade (23/100 RQD, P/E N/A, ROIC -35.0%, cap $891.8M) and JBIO (Jade Biosciences Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $905.6M). Among the 5-stock peer group, OBX leads on earnings multiple (N/A) while OBX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OBX?

Per OBX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002130606), Obsidian Therapeutics Inc. generated $0 in revenue, -$100.6M in net income, and -$90.5M in free cash flow against $88.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OBX trading relative to its 50-day, 200-day, and 52-week technical levels?

OBX last traded at $14.52 (-0.48% on volume of 248,155 shares), positioning the stock -5.04% below its 50-day simple moving average ($15.29) and -15.97% below its 200-day simple moving average ($17.28). Across its 52-week range of $11.52 to $49.97, OBX sits at the 7.8% percentile with a 14-day RSI of 55.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($12.71 to $16.33).

OBX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Why is OBX stock moving today?

Why OBX Stock slipped -0.48% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Direct Sub-Reports: OBX RQD Cockpit OBX 12M Forecast OBX Earnings & Move OBX Dividends & DRIP OBX Insiders & 13F OBX Whale Options OBX Profit Sankey OBX News & Why